Ir presentation 062314

Empowering Personalized
Cancer Treatment
Summer 2014
062314

2014 Cancer Genetics, Inc. | NASDAQ: CGIX | 2
Forward-Looking Statement
This presentation contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development and potential opportunities for Cancer
Genetics, Inc. products and services or Gentris, Inc. products and services., along with other
statements about the future expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that are not historical fact
(including, but not limited to, statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates") should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent
in the development and/or commercialization of potential products, risks of cancellation of customer
contracts or discontinuance of trials, risks that we will not reach agreement on definitive acquisition
agreements with Gentris, or that the Gentris and/or BioServe transactions will not close or, if either or
both closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials
or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property
rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013
and 10-Q for the quarter ended March 31, 2014 along with other filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer
Genetics disclaims any obligation to update these forward-looking statements.

2013 Was a Year of Significant Progress and
2014 Shows Continued Success
 54% full year revenue growth 2013 over 2012 and 45% growth Q1, 2014 over Q1, 2013.
 Test volume grew 63% to 10,771 tests in 2013 over 2012 and 45% to 2,772 tests in Q1, 2014 over Q1, 2013.
 Tripled Gross-Profit Margins to 26% in 2013.
 Closed 2 follow-on offerings on NASDAQ totaling ~$60+ Million.
 Launched 6 proprietary genomic-based diagnostic tests for lymphomas (CLL/SLL, DLBCL, FL, MCL), kidney cancer and cervical
cancer.
 Launched the CALR mutation analysis test targeting ~3 Million patients in the US with MPN.
 Received 3 patent awards covering CGI’s diagnostics for hematologic and kidney cancers.
 Expanded key biopharma relationships with Gilead and Roche driving adoption of CGI’s genomic tests nationally and
internationally.
 Progressive advancements to the management team and board of directors with
experienced and seasoned industry leaders.
 Expanded collaborations and partnerships with world-class institutions including
J.V. with Mayo Clinic in Generation Sequencing: OncoSpire Genomics.

Molecular Diagnostics are Changing our Understanding of Cancer
While Providing New Tools to Diagnose & Treat Patients
Our unique focus & approach supports the entire cancer care continuum
Personalize
therapeutic plan and
treatment options
DIAGNOSIS PROGNOSIS THERANOSIS
Assist in patient
outcome and disease
management
What drug(s) to give, how
much, and when?
What are my survival
prospects?
Do I have cancer and
what type?
Use genomics to provide
an accurate and definitive
typing of the cancer
Proprietary Products Focused Oncology Lab Comprehensive Report
Integrated Molecular Diagnostic Testing Brings Benefits
Across the Entire Oncology Ecosystem

CGI’s Mission is to Personalize and Improve the
Success Rate in Cancer Treatment
Integrating & Delivering Genomic Information About a Patient’s Cancer
Can Improve Care & Reduce Cost
Phenotypic &
Physical Examination
Morphologic &
Pathological Analysis
Large & Multiple
Specimens Required
Significant Delays to
Treatment
Traditional Approach
Biomarkers and
Companion Diagnostics
Genomic Analysis &
Proprietary Algorithms
Reduced Size and
Number of Specimens
Improved Diagnoses &
Treatment Plans
Our Approach: Personalized Medicine
Target For Tomorrow
25%
Situation Today Source: Clinical Trends in Molecular Medicine, Vol. 7, Issue 5
100%
Success Rate Target Success Rate

The Acquisitions of BioServe India and Gentris Corporation Provide
Significant Market Upside & Improve CGI’s Competitive Position
• Access to high-growth Indian diagnostics
market – projected to grow at 15-20% per
annum for the next decade.
• Accelerates next-generation sequencing
development and validation of targeted hot
spot oncology panels.
• Cost-effective expansion of genomic
analysis & informatics capabilities with state
of-the-art 14,000 sq. foot lab.
BioServe India
• Growth potential in integrating our oncology-
focused testing capabilities with Gentris’
high-value contracts.
• Expansion of Gentris’ capabilities and
portfolio to include oncology-focused
pharmacogenomics services.
• 24,000 sq. foot lab space (CLIA/CAP/GLP)
with NGS, genotyping, and gene expression
test capabilities.
Gentris Corporation

Unique, Scalable and Multifaceted Business Model With A Focus On
Providing A Complete Solution
Suite of Products and Services Provides Multiple Growth Drivers and Value to Multiple Parties:
Clinical Community, Biopharma & Medtech
CLINICAL SERVICES
 Differentiated and complete
disease-focused solutions
 Superior turnaround times
 World-class expertise in
genomics and cytogenetics
 Serving community hospitals and
labs through unique Expand Dx™
program
BIOPHARMA PARTNERSHIPS
 Biomarker and companion
diagnostic development
 World-class genomics and
bioinformatics
 Drug-specific and cancer-
specific assays
 Comprehensive focus in
hematologic and urogenital
cancers
PROPRIETARY PRODUCTS
 Proprietary molecular
diagnostics & FISH probes
 Clinically validated
 IP-protected
 Sold globally
 Probe manufacturing leverages
low-cost, high scale facility in
India

Our Target Markets in Oncology Testing Comprise
Over 615,000 New Lives Annually in the U.S.
Ability to Impact Over 615,000 New Lives Annually in the U.S.
Source: American Cancer Society
156,420
2014 Estimated New Cases
(U.S.)
Death Rate 35%
Hematological:
Lymphoma, Leukemia, M. Myeloma
371,610
(U.S.)
Death Rate 16%
Urogenital:
Kidney, Bladder & Prostate
86,970
(U.S.)
Death Rate 31%
Gynecological:
Cervical, Endometrial & Ovarian
6 Products Launched in Target Segments
Over $6Bn in Annual U.S. Spend on Lab Testing In These Categories

6 Proprietary Diagnostic Products
Commercially Launched & In Market
Incidence Indication
Lymphoma & Leukemia Microarrays (MatBA®)
106,770
(Annual New Cases, Global)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
142,360
Diffuse Large B-Cell Lymphoma
62,300
Follicular Lymphoma
17,795
Mantle Cell Lymphoma
Kidney Cancer Microarray (UroGenRA®)
274,000
Kidney Cancer
Cervical Cancer DNA-FISH Probe (FHACT®)
1,750,000
(Annual New Cases, US)
HPV+ Low Grade Cervical Lesions
Over 2.3 Mn Combined Annual New Cases Globally

Product Pipeline
Research &
Discovery
Clinical
Development
Commercial
Development
Launch &
Market Entry
Indication Development Stage
Lymphoma & Leukemia Microarrays (MatBA®)
Multiple Myeloma
Bladder and Prostate Cancer Microarrays (UroGenRA®)
Bladder Cancer
Prostate Cancer
HPV-Associated Cancer DNA-FISH Probe (FHACT®)
Head & Neck Cancer
Urogenital Cancer Microarrays (UGenRA™)
Cervical Cancer
Endometrial Cancer
Ovarian Cancer

Despite Improved Cancer Care, Case Numbers for
Hematologic Cancers are Still Rising
Genomics-Based Tests like MatBA® are Critical and Improve
the Management and Cost of Hematologic Cancers
Source: Genzyme & Nature Source: National Cancer Institute, National Center for Health Statistics, SEER
Dataset of Incidence & Mortality, FDA
1 2 5
12
89
100 80 60 30 2
Number of Years Ago
11.1
12.6
15.5
18.5
20.0 19.7 20.5 21.2
5.6 6.2 7.1 7.9 8.7 8.2
6.9 7.3
1975 1980 1985 1990 1995 2000 2005 2010
Incidence Rate Survival Rate
Identified Leukemia & Lymphoma Subtypes Incidence & Survival Rates for NHLs
(US Only, per 100,000)

MatBA®-CLL/SLL Improves Risk
Stratification & Outcome Prediction
 Validated in Collaboration w/ Dr. Kanti Rai & Dr. Nicholas Chiorazzi (NSLIJ); 2 Datasets, 322 specimens
 Additional Validations being conducted w/ HUMC & Dana Farber; 2 Cohorts, 350+ specimens
█ Favorable
█ Intermediate
█ Unfavorable
█ Favorable/
Intermediate
(no distinction)
38% of cases in our study have
a favorable prognosis falling
under "watch & wait" approach.
8% of cases with unfavorable
prognosis missed by FISH and
caught using MatBA®-CLL/SLL.
Impact on therapy selection &
clinical management of CLL
patients.
Genomic Aberrations Reported
by FISH:
4
Genomic Aberrations Reported
by MatBA®-CLL/SLL:
20
85%
15%
FISH
23%
39%
38%
(Current Method) (CGI Method)

MatBA® can Group Patients into Risk Groups & Prognostication Classes
MatBA®- CLL / SLL is a diagnostic tool and
prognostic indicator for patient stratification
and improved patient management
 Being actively used in clinical care, in clinical trials and in
validation programs with Dana Farber, MSKCC and
HUMC
 20 key genetic events/sites classify CLL patients as
having the potential for
Poor outcome = High risk
Intermediate outcome = Intermediate risk
Good outcome = Low risk
Detection of specific genomic imbalance in
CLL/SLL by MatBA®-CLL/SLL correlates
patient risk with time to first treatment
(TTFT) and shorter overall survival (OS)
 Patients classified as high risk showed a shorter TTFT
compared to those classified as low or intermediate risk
 Patients classified as high risk had significantly shorter OS
times than those classified as low or intermediate risk
 Provides additional risk stratification between low and
intermediate risk patients, not currently available in other
tests
Time to First Treatment (TTFT)
Time (months)
Time (months)
Proportion
Surviving
ProportionTreatment-Free
–GOOD (n=74)
–INTERMED (n=107)
–POOR (n=47)
–GOOD (n=74)
–INTERMED (n=107)
–POOR (n=47)
P = 0.090
P = 0.001
P < 0.001
P = 0.010
Overall Survival (OS)
Leukemia & Lymphoma – Houldsworth, et. al Sept. 18, 2013

UroGenRA®-Kidney Can Guide Management of Patients with Renal
Masses and Appropriate Treatment Selection
Clinical Benefits Include Reduction in Number of Highly Invasive Procedures and Time to
Treatment Initiation, and Better Informed Treatment Selection
Development of diagnostic algorithm
 >600 RCC malignant subtypes (in-silico: SNP)
 >100 malignant and benign renal neoplasms (in-house: aCGH & FISH)
Retrospective in-house FFPE validation (n>190) CCF
 100% diagnostic yield
 97% diagnostic sensitivity to distinguish benign from malignant renal neoplasms
 93% sensitivity to distinguish malignant RCC subtypes
 C. Magi-Galluzzi and E. Klein (Cleveland Clinic)
Prospective ongoing percutaneous core needle biopsy (n>50) MSKCC
 Demonstrated ability to diagnose pathologically “unclassifiable” biopsies prior to surgical
intervention
 J. Coleman and J. Durack (MSKCC)
PROBLEM
Men and women with renal masses often
undergo unnecessary nephrectomy for
accurate diagnosis and experience delay in
treatment
SOLUTION
UroGenRA® will detect genomic aberrations in a single assay
permitting accurate diagnosis (benign vs malignant, and
malignant subtype) guiding appropriate management and
treatment strategies

FHACT® - A New Genomic Aid In The Screening &
Management Of Cervical Cancer
FHACT® Provides Critical Information Which Reduces
Unnecessary and Costly Colposcopies
Cervical cancer effects nearly 500,000 women globally each year with
nearly 80% in developing countries.
Today, all these women are
referred for colposcopy.
Women with abnormal or unclear Pap smears
55 Million
Pap smears per year
3.5 Million
Pap smears come back
as unclear/abnormal
2 Million
biopsies performed
12,000
cases of cervical cancer

FHACT® Provides Information for Developing Treatment Plans
Potentially Reducing Healthcare Costs & Procedures
FHACT® is the Only 4 Color FISH Probe that can be Used for Cervical Cancer Screening
as Additional Testing Before Referral for Colposcopy
Global Validation PartnersGenomic Amplification by Disease Category
Source: P. Luhn, J. Houldsworth, et al., Gynecologic Oncology (2013)
5 10
19 20
0
20
40
60
80 ptrend = 0.01
6 9 9
20
0
20
40
60
80 ptrend = 0.02
6 9 7 12
0
20
40
60
80 ptrend = 0.03
3 8 12 12
0
20
40
60 ptrend = 0.001
<CIN2
& NLIM
(n=11)
<CIN2
& LSIL
(n=20)
CIN2
&/or HSIL
(n=10)
CIN3+
(n=7)
<CIN2
& NLIM
(n=11)
<CIN2
& LSIL
(n=20)
CIN2
&/or HSIL
(n=10)
CIN3+
(n=7)
FHACT® detects irreversible changes in
cervical cells caused by HPV.

Large, Targeted Market Opportunities
Target Markets Commercialization Strategy
Community Hospitals
Regional Cancer Centers
Oncologists and Pathologists
 Continue to growing sales force that calls on hospitals
and regional laboratories
 Plan development of national footprint through Expand
Dx™
Biotechnology Companies
Pharmaceutical Companies
 Leverage clinical infrastructure and proprietary product
portfolio for testing services that support clinical trials
 Expand sales emphasis of Select One®
Emerging Markets
 Enhance distributor base in select emerging economies
 Partner with leading local cancer care providers and
hospitals to provide probes, arrays and clinical services
 Collaborate to create and validate microarrays and other
proprietary products
 Accelerate launch of large scale studies
Universities and Research Centers

Unique Service Offering Developed to Enable Community Hospitals
to Improve Cancer Outcomes & Treat Patients Locally
 Delivers better outcomes to
community hospitals and laboratories
 Enables community hospitals to bring
“state-of-the-art” genomic testing to
patients
 Brings personalized medicine to the
community hospital vs. just at
academic and teaching hospitals
 Allows community hospitals to keep
patients and treat them locally
 Improving care and quality is critical to
maintaining reimbursement for
community hospitals
$600,000 - $800,000 USD in Testing
Opportunity on Average per Hospital
Expanding & Developing Cancer Care is a
Top Priority for Hospital CEOs & CFOs
4,000 to 5,000 Community Hospitals
& Laboratories in the U.S.
85% Of All U.S. Cancer Patients are Initially
Diagnosed in Community Hospitals &
Laboratories

Through Acquisition, Clinical Trial Services Show Strong
Growth and Robust Pipeline
Gentris Provides Pharmacogenomic Clinical Trial Services to Several Large Pharma
Companies Including Merck, Novartis, Otsuka, Eisai and Bristol-Myers Squibb
GROWTH IN CGI’s SELECT ONE®
CONTRACTS ($000)
21%
55%
ONCOLOGY DRUGS ASSOCIATED WITH
BIOMARKER(S)
$300
$2,700
$8,500
$14,200
2011 2012 2013 2014
Approximate value of contracts with biotech and pharma clients
2011 2016
Source: Company Analysis and Management Estimates

Over 6,800 Oncology Trials in the US
Aligned with our Core Markets
Number of Open Clinical Trials (U.S.)
1,439 1,453
2,178
1,765
Lymphoma Leukemia Urogenital HPV-Associated
Source: www.clinicaltrials.gov

Gilead is Currently Using a Comprehensive Panel of CGI Services &
Proprietary Products in National & International Trials for
Hematologic Cancers
The Gilead Relationship Exemplifies the Significant Upside Potential of
CGI’s Select One® Offering
Highlights
 Comprehensive, biomarker-based patient profiling will help risk stratification and response monitoring
 Improved patient profiling will result in improved trial efficacy for Gilead
 Testing will occur across several methodologies, including flow cytometry, FISH, sequencing and
mutation assays, and MatBA® microarrays
 CGI provides biomarker driven insight regarding patient targeting and potential outcomes
 Trials cover both national and international locations with all patient specimens being processed in
Rutherford, New Jersey
CGIX Press Release: Cancer Genetics, Inc. Selected By Gilead Sciences, Inc. to Provide Clinical Trial Services for International Trials in Chronic Lymphocytic Leukemia

Roche Partnership
Expanding Market Presence Internationally
“By expanding our relationship, we are strengthening our ability to provide patients the best
service possible.” Alvaro Soto, Roche Servicios, Central America & Caribbean General Manager
Highlights
CGI provides genomic and biomarker testing services to 14 countries
in Central America and the Caribbean.
 CGI won a global RFP to help a strategic personalized medicine initiative for Roche Servicios (Latin
America)
 Roche sends all patient samples to the Rutherford facility where they are catalogued and processed
 CGI interacts with both Roche and the hospital staff (pathologists, oncologists and nurses) and
supports delivery of reports through an online HIPAA compliant portal
 CGI and Roche expanded this relationship in 2013 and will begin developing workshops and training
programs to drive adoption of biomarker-based cancer diagnostics throughout Central America and
the Caribbean
 CGI and Roche recently further expanded this relationship with an exclusive multi-year deal in which
CGI will develop a center of excellence for lung cancer testing utilizing Roche’s FDA-Approved
cobas® platform
CGIX Press Release: Cancer Genetics, Inc. selected by Roche Servicios S.A. to provide services for the diagnosis and personalization of oncology treatment
CGIX Press Release: Cancer Genetics, Inc. expands relationship with Roche Servicios S.A.

Collaborations with Premier Cancer Research Institutions
Leading Differentiated Research & Driving Product Adoption
Research Collaboration/
Licensing
Clinical
Services
Partnership
Highlights
   Kidney Cancer, DLBCL, MCL & FL

 Joint Venture Focused on Oncology & Next
Generation Sequencing
  Cervical Cancer
  DLBCL
   CLL
   Cervical Cancer & DLBCL
  Cervical Cancer
  Kidney Cancer
   DLBCL, Head & Neck Cancers
   CLL

Mayo Clinic Joint Venture
Investing in the Future – OncoSpire Genomics
The Value and Focus of Next Generation Sequencing is Moving from Platforms to Clinically
Relevant, Disease-Specific Applications
Highlights
 JV, based in Rochester, MN, will develop clinical diagnostic products and services on NGS platform(s)
in areas of high clinical need
 Three initial projects in key oncology categories selected by the SRC (Scientific Review Committee):
Lung Cancer, Multiple Myeloma, Follicular Lymphoma
 CGI commits up to $6 M over initial three year period (2013 to 2015-16 expected)
 Mayo commits to “in-kind” services and support, use of facilities, NGS capabilities and access to
biorepository
 Joint Venture is exclusive in the project areas selected by CGI & Mayo
 Important company update and analyst day held November 22, 2013
Next Generation Sequencing in Oncology

OncoSpire Genomics
Projects are Unique and Have High Value
1.6 million
new cases
200,000
new cases
20,920
new cases
Informed
Discovery
Clinical
Development
Commercial
Development
Market Entry
(with partners)
Lung Cancer
Multiple Myeloma
Follicular Lymphoma
Selected Projects Have Significant Clinical Value & May Yield Multiple Focused
Panels to Become the Standard of Care in NGS-Based Oncology Management

Strong History of Growth
CGI Revenue & Clinical Volume Trends (2009 – 2013)
54% Full Year 2013 Revenue Growth
$1.67
$2.52
$3.02
$4.30
$6.61
2009 2010 2011 2012 2013
2,321
3,146
3,622
6,610
10,771
2009 2010 2011 2012 2013
Total Revenue ($Mn) Clinical Volume (Tests Processed)

Strong History of Growth - Revenue & Clinical Volume Trends
(Q1 Comparison 2012-2014)
$835
$1,219
$1,430
Q1, 2012 Q1, 2013 Q1, 2014
Total Revenue ($000)
1,610
1,911
2,772
Q1, 2012 Q1, 2013 Q1, 2014
Clinical Volume (Tests Processed)

Summary Statement of Operations
(Q1 Comparison 2012-2014)
Income Statement Item Q1, 2012 Q1, 2013 Q1, 2014
Revenue $835 $1,219 $1,430
Gross Profit 12 149 140
Gross Margin (%) 1.4% 12.2% 9.8%
Research & Development (R&D) 524 491 597
Sales & Marketing (S&M) 340 396 749
General & Administrative (G&A) 936 1,571 2,731
Operating Profit (Loss) (1,788) (2,309) (3,937)
Net Income (Loss) (1,072) 2,360 (2,486)
$ in thousands
Actual 03/31/14
Cash & Cash Equivalents $41,315
Stockholders’ Equity 43,635
$ in thousands
Summary Balance Sheet

Consistent Focus on Gross Profit Improvements
Additional Efforts Focused Operationally in US & India
Gross Profit Margin Highlights of Initiatives
(52%) (39%) (3%)
9%
26%
(1,000)
(800)
(600)
(400)
(200)
0
200
400
600
800
2009
2010
2011
2012 2013
$inThousands
 Decrease CGI Costs for
Development & Services
 Migrate DNA manufacture and
NT Kits for CGI probes
 Develop remove G-Band analysis
capability
 Develop remote FHACT®
analysis capabilities
 Move entire probe manufacturing
& assembly

Multiple Customer Types Provide Diversified Revenue Mix
With Covered Lives Already in Place
Selected Payors
Direct Bill Customer Types
Biotechs
Pharmas
Academic
Cancer Facilities
Community &
Regional Labs
72+ million covered lives through multiple payors:
13%
21%
58%
3%
5%
Medicare
3rd Party
InsuranceCompanies,
Hospitals
& Care
Facilities
Payor Revenue Mix 2013
Reimbursement Based Direct Bill / Pay Based
3rd Party Insurance
Medicare
Grants
2013
Probes
Companies, Hospitals
& Care Facilities

Experienced and Focused Management and Boards
Scientific Advisory Board
Andrea Califano, Ph.D.
Chairman of the Columbia Initiative for Systems Biology
Associate Director for Bioinformatics, Herbert Irving Comprehensive
Cancer Center
Timothy A. Chan, M.D., Ph.D.
Principal Investigator, Human Oncology and Pathogenesis Program
at Memorial Sloan-Kettering Cancer Center
Riccardo Dalla-Favera, M.D.
Director, Institute for Cancer Genetics at Columbia University
Hans-Guido Wendel, M.D.
Principal Investigator, Cancer Genetics Laboratory at Memorial
Sloan-Kettering Cancer Center
Vundavalli V. Murty, Ph.D.
Director, Cancer Cytogenetic Laboratory and Molecular Pathology at
Columbia University
Andrew D. Zelenetz, M.D., Ph.D.
Chief of Lymphoma Service and Head of Molecular Hemo-Oncology
Laboratory, Department of Medicine at MSKCC
Raju Chaganti, Ph.D., FACMG Founder
• 35+ years in cancer research; 38 at MSKCC
• Major discoveries in cancer genomics
• Published 350+ articles, 4 patents
Panna Sharma President & CEO
• 15+ years as advisor to global life science & healthcare cos.
• Founded TSG Partners
• Chief Strategy Officer, iXL (IIXL)
Edward J. Sitar Chief Financial Officer & Treasurer
• 30+ yrs in finance & deal making in the healthcare industry
• Healthagen, ActiveHealth Management, Cadent Holding, MIM Corporation
(Bioscrip), Vital Signs, Zenith/Goldline Pharmaceutical, Coopers &
Lybrand
Jane Houldsworth, Ph.D. Vice President of R&D
• 25+ years in translational oncology research
• Published 50+ articles, 4 patents
• NIH grantee
Chairman of the Board, | Keith Brownlie, CPA | Edmund Cannon | Raju Chaganti, Ph.D.
John Pappajohn | Franklyn Prendergast, M.D., Ph.D. | Paul Rothman, M.D. | Panna Sharma
Board of Directors
Officers & Management Team

Consistent Achievement of Milestones
Expected in Coming Quarters
 Increasing covered lives market access through
additional payers & health care organizations
 Launching multi-marker NGS panel for lymphoid
malignancies
 Additional international agreements with life science
tools companies for DNA Probes and product
distribution in key geographies
 MatBA® – Next phase of data and results from Dana
Farber and HUMC studies to help support value and
reimbursement
 Pursuing CE approval for IVDD use of FHACT® in
E.U.
 Additional news on biopharma partners &
relationships
 Pursuing additional indications for UroGenRA®-
Kidney microarray
 Portfolio and analyst update meeting (June)
 Close of BioServe transaction (Q3, 2014)
 Accelerating Market Traction – 54% growth during 2013 over 2012
 Migrated DNA-FISH Probe Manufacturing to India reducing cost, increasing
capacity and improving operational flexibility
 Launched UroGenRA®-Kidney, a unique microarray for kidney cancer
diagnosis in collaboration with MSKCC
 Collaborative Study of UroGenRA®-Kidney with Cleveland Clinic
demonstrated 93% diagnostic accuracy
 Launched FHACT® outside the U.S. in collaboration with the National
Cancer Institute research publication
 Launched FHACT® as an LDT under CLIA in the U.S.
 Received CLIA Approval for MatBA®-MCL (Mantle Cell Lymphoma)
 Finalized Agreement with Multiplan and Three Rivers which gave us
access to 72+ million covered lives
 Launched OncoSpire Genomics – A Next Generation Sequencing Joint
Venture with Mayo Clinic and announced initial set of projects (lung cancer,
multiple myeloma & follicular lymphoma)
Recent
Accomplishments
Upcoming Milestones
and Value Drivers

For further information, please contact us at ir@cancergenetics.com
Cancer Genetics, Inc.
Meadows Office Complex
201 Route 17 North
Rutherford, NJ 07070
(201) 528-9200
www.cancergenetics.com

IP Position and Detailed Global Strategy
 Strong and growing portfolio in molecular-focused patents for disease
identification and stratification
 IP-based on unique algorithms across a broad group of chromosomal regions
 Validation of specific clinical endpoints that are associated with
particular disease outcomes or decisions
 Filing and maintenance of trademark portfolio
Tool for Diagnosis and Prognosis of Mature B-Cell Neoplasms
 US Issued Patent 8,580,713
 Europe 10803548.6
 India 6657/DELNP/2012
 Canada 2,785,656
Methods of Analyzing Chromosomal Translocations Using
Fluorescence In Situ Hybridization (FISH)
 Canada 2,447,320
Panel for the Detection and Differentiation of Renal Cortical
Neoplasms
 US 14/078,726
 Europe 08844570.5
Methods for Detecting Human Papilloma Virus-Associated
Cancers
 US 13/227,027
 US 13/474,111
 PCT/US2011/050681
Methods and Tools for the Diagnosis of Female
Gynecological Cancers and Precancers
 US 61/581,350

BioServe India – Profile & Capabilities
Cutting-Edge Genomic Services:
Next Generation Sequencing, Genotyping & DNA Synthesis
 Founded in 2002 and located in Hyderabad, Andhra Pradesh.
 14,000 square foot NABL* accredited facility for its GMO services, equipped
with NGS capabilities.
 33 employees including 19 scientific staff members and 7 in sales.
 Has developed next generation sequencing panels for oncology.
 Infrastructure and scientific expertise required to integrate CGI’s DNA-FISH
probe manufacturing and proprietary FHACT® business into the Indian
biotech market that accounts for >25% of global cervical cancer deaths.
 Current customers include Center for Cellular and Molecular Biology, Center
for DNA Finger Printing and Diagnostics and Dr. Reddy's labs.
 Backed by VenturEast, a pioneering healthcare-focused venture capital fund
manager based in India with ~$300 Million under management.
$65 Bn
$100 Bn
2013 2015
Indian Healthcare Sector
Dx & Medical Equipment
$3.3 Bn
$5 Bn
2013 2015
15-20%
Growth
Source: PM Live Pharmaceutical
Industry News & KPMG
*NABL: National Accreditation Board for Testing and Calibration Laboratories (equivalent to CLIA).

Ir presentation 062314

More Related Content

What's hot

Viewers also liked

Similar to Ir presentation 062314

More from RedChip Companies, Inc.

Recently uploaded

Ir presentation 062314